The current approach of atrial fibrillation management

Abstract

Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Aging populations coupled with improved outcomes for many chronic medical conditions has led to increases in AF diagnoses. AF is also known to be associated with an increased risk of adverse events such as transient ischemic attack, ischemic stroke, systemic embolism, and death. This association is enhanced in select populations with preexisting comorbid conditions such as chronic heart failure. The aim of this review is to highlight the advances in the field of cardiology in the management of AF in both acute and long-term settings. We will also review the evolution of anticoagulation management over the past few years and landmark trials in the development of novel oral anticoagulants (NOACs), reversal agents for new NOACs, nonpharmacological options to anticoagulation therapy, and the role of implantable loop recorder in AF management.

Cardiac Arrest Following Treatment With Diltiazem for Atrial Fibrillation With Rapid Ventricular Response

“…Treatment of primary AF is based on the patient’s stability. Unstable patients require immediate electrical cardioversion and anticoagulation for four weeks after cardioversion [ 2 ]. The unstable patients include those with respiratory distress, poor perfusion, altered mental status, or shock.…”

“…Furthermore, because these agents block the AV node, there is a risk of heart blocks with their use. Digoxin or amiodarone can be used if BBs and CCBs are ineffective or contraindicated [ 1 , 2 ], but the former has too slow an onset to be used in the ED setting.…”

Atrial Flutter: up‐to‐date Problem Evaluation with Clinical Positions

“…Целевой контроль частоты ТП может быть достигнут путем комбинации перечисленных препаратов: бета-адреноблокаторов или антагонистов кальция с дигоксином или амиодароном, а также амиодарона с дигоксином [43]. В то же время, по данным German Ablation Registry [44] [50,52]. Однако не следует забывать, что основные побочные эффекты амиодарона, носящие экстракардиальный токсический характер, напрямую связаны с длительностью его применения и наблюдаются более чем в 50 % случаев постоянного приема препарата более 1 года [2,45].…”

The prevalence, management, and thirty-day outcomes of symptomatic atrial fibrillation in a Tanzanian emergency department

“…The diagnosis of AF requires both access to electrocardiography (ECG) and expertise to interpret this diagnostic test which are not universal across SSA [12] , [13] . Moreover anticoagulation; the cornerstone of long-term AF management, requires therapies, laboratory monitoring, and routine outpatient follow-up that are not widely available in SSA settings [10] . The CHADS-VASC risk stratification tool is used worldwide to assess the need for anticoagulation [14] , but existing evidence suggests that this tool is used inconsistently in SSA.…”